Retatrutide and trizepatide represent a new class of medications that act on both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These multifunctional receptor agonists exhibit significant therapeutic benefits in the treatment of type 2 diabetes. Retatrutide, a once-weekly subcutaneous injectio